Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $189 - $431
-2 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$207.3 - $300.31 $414 - $600
2 New
2 $0
Q2 2018

Aug 13, 2018

SELL
$101.55 - $313.9 $203 - $627
-2 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $186 - $298
2 New
2 $0

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.35B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Avantax Planning Partners, Inc. Portfolio

Follow Avantax Planning Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Planning Partners, Inc. with notifications on news.